FDA Approves Agile Therapeutics, Inc.’s Twirla (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120

von , 14.02.2020, 23:46 Uhr

Twirla is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX) (Agile or the Company), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Twirla (levonorgestrel and ethinyl estradiol) transdermal system. INDICATION

Meistgelesene Nachrichten

24h 48h 72h 7 Tage 30 Tage 3 Mo 12 Mo 24 Mo